- A newly developed mRNA-based prostate cancer (PCa) liquid biopsy test has a diagnostic accuracy of >92%.
- This accuracy is significantly higher than that of the PSA test.
Why this matters
- PCa is the most common noncutaneous cancer in men.
- Reliable PCa biomarkers are an unmet need.
- Using a publicly available PCa transcriptome sets, a putative PCa signature was identified.
- Candidate genes were assessed using PCa and normal prostate cell lines and validated in tumor tissue and The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset.
- Using 2 datasets (PCa, n=132; benign prostatic hyperplasia, n=44; controls, n=55) and classification algorithm analyses, an artificial intelligence PCa model was constructed.
- Funding: Wren Laboratories.
- Transcriptomic analysis identified a 27-gene blood signature for PCa.
- Candidate genes were detectable and upregulated in PCa cell lines and tumor tissue.
- Blood and tumor tissue gene expression significantly correlated (r=0.56).
- A 0-100 score, based on normalized algorithmically analyzed gene expression, was developed (score ≥20=positive).
- The diagnostic accuracy of the test (PROSTest) was 92.4%; sensitivity and specificity were 94.4% and 89.7%, respectively.
- The score significantly decreased after surgical resection and increased during biochemical recurrence (biochemical recurrence detection rate, 96%).
- PSA accuracy (>10 ng/mL) in PCa diagnosis was 48% (P<.0001>